公开(公告)号：WO2006003427A8

公开(公告)日：2006-03-09

申请号：PCT/GB2005002608

申请日：2005-07-01

Applicant: CELLTECH R&D LTD ,  TERRETT JONATHAN ALEXANDER

Inventor： TERRETT JONATHAN ALEXANDER

IPC: A61K38/17 ,  C07K14/47 ,  C12Q1/68 ,  G01N33/574 ,  A61K39/395 ,  G01N33/53

CPC classification number: C12Q1/6886 ,  A61K38/1709 ,  C07K14/47 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/574 ,  G01N2500/00 ,  G01N2800/52

Abstract: The present invention provides a polypeptide, KIAA1455, of use in the treatment and/or prophylaxis of carcinoma. Also provided are agents which interact with or modulate the expression or activity of the polypeptide, methods for the identification of such agents and the use of KIAA1455 in the diagnosis of carcinoma.

Abstract translation: 本发明提供了用于治疗和/或预防癌症的多肽KIAA1455。 还提供了与多肽的表达或活性相互作用或调节的试剂，用于鉴定这些试剂的方法以及KIAA1455在癌症诊断中的应用。

公开(公告)号：WO2005117984A2

公开(公告)日：2005-12-15

申请号：PCT/GB2005002084

申请日：2005-05-25

Applicant: CELLTECH R&D LTD ,  EATON MICHAEL ANTHONY WILLIAM ,  NORMAN TIMOTHY JOHN ,  PORTER JOHN ROBERT

Inventor： EATON MICHAEL ANTHONY WILLIAM ,  NORMAN TIMOTHY JOHN ,  PORTER JOHN ROBERT

IPC: A61K47/48

CPC classification number: A61K47/542 ,  A61K47/60

Abstract: The present invention provides an albumin-binding compound essentially of the following elements: a spacer group, a water-soluble bridging group, a fatty acid chain and an acidic group characterised in that the acidic group is attached to the distal end of the fatty acid chain. The invention also provides an albumin-binding compound to which one or more biologically active moieties are attached.

Abstract translation: 本发明提供了基本上具有以下元素的白蛋白结合化合物：间隔基，水溶性桥连基团，脂肪酸链和酸性基团，其特征在于酸性基团连接到脂肪酸的末端 链。 本发明还提供了与一个或多个生物活性部分连接的白蛋白结合化合物。

公开(公告)号：WO2005023300A2

公开(公告)日：2005-03-17

申请号：PCT/GB2004003674

申请日：2004-08-27

Applicant: CELLTECH R&D LTD ,  HUDSON LINDSEY JANE

Inventor： HUDSON LINDSEY JANE

IPC: A61P35/00 ,  C07K14/705 ,  C07K16/28 ,  C07K16/30 ,  A61K39/395 ,  A61K39/00

CPC classification number: C07K14/705 ,  A61K2039/505 ,  C07K16/30 ,  C07K2317/34

Abstract: The present invention provides a polypeptide, MAL2, of use in the treatment and/or prophylaxis of carcinoma, in particular liver cancer, stomach cancer and/or colon cancer. Also provided are agents which interact with or modulate the expression or activity of the polypeptide, methods for the identification of such agents and the use of MAL2 in the diagnosis of said carcinoma.

Abstract translation: 本发明提供了用于治疗和/或预防癌症，特别是肝癌，胃癌和/或结肠癌的多肽MAL2。 还提供了与多肽的表达或活性相互作用或调节多肽的表达或活性的试剂，鉴定这些试剂的方法和MAL2在诊断所述癌症中的用途。

公开(公告)号：WO2004100986A2

公开(公告)日：2004-11-25

申请号：PCT/GB2004002098

申请日：2004-05-13

Applicant: CELLTECH R&D LTD ,  BIRD JOHN ,  MCLOUGHLIN SHEILA BRIDGET ,  BARNES MATTHEW JOSEPH

Inventor： BIRD JOHN ,  MCLOUGHLIN SHEILA BRIDGET ,  BARNES MATTHEW JOSEPH

IPC: A61P29/00 ,  C12Q1/37 ,  A61K39/395

CPC classification number: C12Q1/37 ,  G01N2500/00

Abstract: The present invention provides the use of a substance capable of inhibiting ADAM 10, an enzyme involved in the shedding of ectodomain CD23, for the manufacture of a medicament for the treatment of allergic diseases, including asthma, atopic dermatitis and allergic rhinitis.

Abstract translation: 本发明提供了能够抑制ADAM 10（涉及胞外域CD23脱落的酶）的物质用于制备用于治疗过敏性疾病（包括哮喘，特应性皮炎和过敏性鼻炎）的药物的用途的用途。

公开(公告)号：BRPI0106682B8

公开(公告)日：2021-05-25

申请号：BRPI0106682

申请日：2001-06-05

Applicant: CELLTECH R&D LTD ,  UCB PHARMA SA ,  UCB SA

Inventor： ANDREW GEORGE POPPLEWELL ,  ANDREW NEIL CHARLES WEIR ,  ANDREW PAUL CHAPMAN ,  DAVID JOHN KING ,  DEREK THOMAS BROWN ,  DILJEET SINGH ATHWAL

IPC: A61K39/395 ,  C12N15/09 ,  A61K39/00 ,  A61K47/48 ,  A61K47/68 ,  A61P19/02 ,  A61P29/00 ,  A61P37/06 ,  C07K16/24 ,  C07K16/46 ,  C07K19/00 ,  C12N1/21 ,  C12N15/13 ,  C12N15/62 ,  C12N15/70 ,  C12P21/02 ,  C12P21/08

Abstract: molécula de anticorpo, variante de molécula de anticorpo, anticorpo, composto, seqüência de dna, vetor de clonagem ou de expressão, vetor de expressão de e. coli, célula hospedeira, processo para a produção da molécula de anticorpo, composição terapêutica ou diagnóstica, uso da molécula de anticorpo, vetor pdnabeng-g1, vetor ptto(cdp870), e, polipeptídeo. apresentam-se moléculas anticorpos contendo pelo menos um cdr derivado de um anticorpo monoclonal de camundongos com especificidade para o tnf(alfa). é também apresentado anticorpo enxertado de cdr em que pelo menos um dos cdrs é um cdr híbrido. são ainda apresentadas seqüências de dna que codificam as cadeias das moléculas anticorpos, vetores, células hospedeiras transformadas e usos das moléculas anticorpos no tratamento de doenças mediadas por tnf(alfa).

公开(公告)号：CA2536099C

公开(公告)日：2015-11-17

申请号：CA2536099

申请日：2004-09-02

Applicant: CELLTECH R&D LTD

Inventor： GLOVER DAVID JOHN ,  SEHDEV MUKESH ,  REEKS DOMINIC GAMBIER

IPC: C12N1/20 ,  C12N1/21 ,  C12N15/72 ,  C12P21/02

Abstract: The present invention provides a method for controlling the partitioning of a recombinant protein between the supernatant and the periplasm in E.coli host cell cultures wherein expression of the recombinant protein by said cells is under the control of an inducible system, which method comprises: a) providing an E.coli host cell culture b) changing the growth rate of theE.coli host cells c) inducing expression of the recombinant protein wherein steps (b) and (c) can be performed in any order or simultaneously; and subsequently d) determining the yield of recombinant protein in the culture supernatant and the E.coli host cell periplasm e) comparing the yield determined in step (d) with the yield determined when at least one other growth rate has been used in step (b) f) selecting a growth rate from the comparison made in step (e) in which the partitioning of the recombinant protein between the supernatant and the periplasm is most suited to the primary recovery of the recombinant protein.

公开(公告)号：IL164923A

公开(公告)日：2012-03-29

申请号：IL16492304

申请日：2004-10-28

Applicant: UCB PHARMA SA ,  CELLTECH R&D LTD

IPC: C07K16/18 ,  A61K38/16 ,  A61K39/395 ,  A61P35/00 ,  C07K16/28 ,  C12N15/13 ,  C12N15/63 ,  C12P21/00

Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.

公开(公告)号：CA2380298C

公开(公告)日：2010-09-28

申请号：CA2380298

申请日：2001-06-05

Applicant: CELLTECH R&D LTD

Inventor： ATHWAL DILJEET SINGH ,  BROWN DEREK THOMAS ,  WEIR ANDREW NEIL CHARLES ,  POPPLEWELL ANDREW GEORGE ,  CHAPMAN ANDREW PAUL ,  KING DAVID JOHN

IPC: C12N15/09 ,  C12N15/13 ,  A61K39/395 ,  A61K47/48 ,  A61P19/02 ,  A61P29/00 ,  A61P37/06 ,  C07K16/24 ,  C07K16/46 ,  C07K19/00 ,  C12N1/21 ,  C12N15/62 ,  C12N15/70 ,  C12P21/02 ,  C12P21/08

Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNF.alpha.. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNF.alpha..

公开(公告)号：AP2092A

公开(公告)日：2010-02-28

申请号：AP2002002690

申请日：2001-06-05

Applicant: CELLTECH R&D LTD

Inventor： ATHWAL DILJEET SINGH ,  BROWN DEREK THOMAS ,  WEIR ANDREW NEIL CHARLES ,  POPPLEWELL ANDREW GEORGE ,  CHAPMAN ANDREW PAUL ,  KING DAVID JOHN

IPC: C12N15/09 ,  A61K39/00 ,  A61K39/395 ,  A61K47/00 ,  A61K47/48 ,  A61P19/02 ,  A61P29/00 ,  A61P37/06 ,  C07K16/24 ,  C07K16/46 ,  C12N1/21 ,  C12N15/00 ,  C12N15/13 ,  C12P21/02 ,  C12P21/08

Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNFa. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNFa.

公开(公告)号：IL156915A

公开(公告)日：2009-06-15

申请号：IL15691503

申请日：2003-07-14

Applicant: CELLTECH R&D LTD

IPC: A61K31/198 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/4406 ,  A61K31/497 ,  A61P3/10 ,  A61P9/00 ,  A61P17/00 ,  A61P17/06 ,  A61P19/02 ,  A61P25/00 ,  A61P29/00 ,  A61P37/00 ,  A61P37/06 ,  A61P43/00 ,  C07C229/34 ,  C07C229/46 ,  C07C233/82 ,  C07C321/22 ,  C07C323/30 ,  C07D213/81 ,  C07D213/89 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D471/04

Abstract: Phenylalanine enamide derivatives of formula (1) are described: wherein R 1 , R x , R y , R z , X and V are as defined in claim 1. The compounds are able to inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders or disorders involving the inappropriate growth or migration of cells.